Summit Therapeutics (SMMT) Given News Sentiment Score of 0.06
News coverage about Summit Therapeutics (NASDAQ:SMMT) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Summit Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.4653260362941 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Summit Therapeutics (NASDAQ:SMMT) traded up $0.92 during midday trading on Friday, reaching $12.28. 37,929 shares of the company’s stock traded hands, compared to its average volume of 68,975. The company has a market capitalization of $170.00, a P/E ratio of -122.80 and a beta of 0.93. Summit Therapeutics has a twelve month low of $8.80 and a twelve month high of $16.86.
Summit Therapeutics (NASDAQ:SMMT) last announced its quarterly earnings data on Wednesday, December 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.53. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.32 million. Summit Therapeutics had a negative net margin of 0.95% and a negative return on equity of 10.90%. equities research analysts predict that Summit Therapeutics will post -0.38 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/summit-therapeutics-smmt-given-news-sentiment-score-of-0-06/1907313.html.
About Summit Therapeutics
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.